Jorge Conde
Showing 16–19 of 19 transcripts.
- a16z17 min
Programming Medicine
The medical field is undergoing a paradigm shift from chemical synthesis to programming living entities like cells, genes, and microbes as direct therapeutics. Four core imperatives—sensing disease, executing treatments, containing activity to specific sites, and self-terminating after success—are now driving the development of advanced therapies such as CAR-T, CRISPR gene editing, and engineered microbiome treatments. This evolution aims to overcome historical safety barriers and treat the thousands of genetic diseases and cancers affecting a significant portion of the global population.
- a16z27 min
Shifting Risk Mindsets, from Tech to Bio
Jorge Conde, Vijay Pande, Jeff Low, Jeffrey Lowe
Bio-hybrid startups face critical challenges in translating novel technologies to traditional biological partners and avoiding the "death by a thousand pilots" trap through strategic deal structures. Founders must carefully position their platforms to capture value in high-impact areas like Phase III failure prediction while isolating asset risks via legal separation to prevent resource drain. Successful execution requires a hybrid approach to funding and partnership, where founders bridge the linguistic gap between tech and bio communities to align reimbursement models with long-term investor expectations.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.
- a16z22 min
Challenges in Healthcare Innovation
The healthcare sector faces a critical efficiency crisis known as Eroom's Law, where rising costs and long timelines for drug discovery are exacerbated by a fundamental lack of biological understanding for complex diseases like Alzheimer's. This challenge is driving a rapid convergence of genomics, artificial intelligence, and engineering, which is transforming medicine from an experimental science into an engineered discipline capable of creating intelligent, logic-based therapies. As the industry shifts from traditional animal models to predictive organ-on-chip systems and embraces digital therapeutics, the alignment of payors, regulators, and innovators is accelerating the delivery of curative precision treatments while extending biological design principles into data storage and manufacturing.